BioCatalystWatch
ARGXWorkspace / ARGX / OverviewCompany library
Price
Market cap
Next catalystDec 2026Empasiprubart (ARGX-117) · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

ARGX-118

Galectin-10

Upcoming / outlook

Empasiprubart (ARGX-117)

Complement C2

PreINDP1P2P3FilingApproved
Upcoming / outlook

Empasiprubart (ARGX-117)

Complement C2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

FB102

CD122

Upcoming / outlook

VYVGART (efgartigimod alfa-fcab)

FcRn

PreINDP1P2P3FilingApproved
Upcoming / outlook

VYVGART (efgartigimod alfa-fcab)

FcRn

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

ARGX-118

Galectin-10

Upcoming / outlook

FB102

CD122

Upcoming / outlook

VYVGART (efgartigimod alfa-fcab)

FcRn

PreINDP1P2P3FilingApproved
Upcoming / outlook

Empasiprubart (ARGX-117)

Complement C2

PreINDP1P2P3FilingApproved
Upcoming / outlook

VYVGART (efgartigimod alfa-fcab)

FcRn

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

ARGX-109

IL-6

PreINDP1P2P3FilingApproved
ARGX-125

PreINDP1P2P3FilingApproved
Adimanebart

MuSK

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Adimanebart

MuSK

PreINDP1P2P3FilingApproved

Adimanebart

MuSK

PreINDP1P2P3FilingApproved

Adimanebart

MuSK

PreINDP1P2P3FilingApproved
FB102

CD122

PreINDP1P2P3FilingApproved
Upcoming / outlook

CD70

Partner / License out

CD70

PreINDP1P2P3FilingApproved
Upcoming / outlook

GARP

PreINDP1P2P3FilingApproved

Approved / commercial

VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)

FcRn

Approved

PreINDP1P2P3FilingApproved

VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)

FcRn

Approved

PreINDP1P2P3FilingApproved

VYVGART (efgartigimod alfa-fcab)

FcRn

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

History / paused

IL-22R1

Empasiprubart (ARGX-117)

Complement C2

VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)

FcRn

PreINDP1P2P3FilingApproved
VYVGART (efgartigimod alfa-fcab)

FcRn

VYVGART (efgartigimod alfa-fcab)

FcRn

VYVGART (efgartigimod alfa-fcab)

FcRn

PreINDP1P2P3FilingApproved
VYVGART (efgartigimod alfa-fcab)

FcRn

VYVGART (efgartigimod alfa-fcab)

FcRn

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ARGX SEC archive